TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05673954

Intervention type: DIAGNOSTIC_TEST
Intervention: C-Read test
Description: C-Read is a reliable and valid clinical tool for quantitatively testing the reading ability of readers of simplified Chinese characters.

Intervention type: DIAGNOSTIC_TEST
Intervention: C-Read test
Description: C-Read is a reliable and valid clinical tool for quantitatively testing the reading ability of readers of simplified Chinese characters.
Study: NCT05523336

Intervention type: OTHER
Intervention: observation
Description: observation and prospective data collection
Study: NCT06346743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Single dose of Fenofibrate will be given at dose of 10mg/Kg along with phototherapy for 24 hours before next blood sampling

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Description: only phototherapy will be given for 24 hours before next blood sampling

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: only phototherapy will be given for 24 hours before next blood sampling
Study: NCT04269161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic control of inspired oxygen
Description: A device will be used to automatically adjust the blend of oxygen and air with the ability to return to manual control as needed.
Study: NCT05198739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Interaction Project (VIP) program
Description: Video Interaction Project (VIP) is a strengths-based, family-centered intervention designed to enhance parenting practices/relationships and child development by promoting positive parenting practices such as pretend play, shared reading, and daily routines. In VIP's core component, a VIP coach video-records the parent / child for 3-5 minutes playing/reading with a provided toy and/or book, then reviews the video with the parent to facilitate self-reflection on the interaction and identifies and reinforces strengths. In the US, VIP is delivered in the context of pediatric primary care visits, with a COVID-19 remote adaptation (see Section 6 for details). Research staff will delivery VIP through video calls with subjects in Brazil.
Study: NCT05177497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: SHR-1701 administered by iv
Study: NCT05059366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Ventilation Grip Device
Description: Manual Ventilation Grip Device is an add-on device placed on a standard valve mask to assist ventilation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Ventilation Grip Device
Description: Manual Ventilation Grip Device is an add-on device placed on a standard valve mask to assist ventilation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Ventilation Grip Device
Description: Manual Ventilation Grip Device is an add-on device placed on a standard valve mask to assist ventilation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Ventilation Grip Device
Description: Manual Ventilation Grip Device is an add-on device placed on a standard valve mask to assist ventilation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2VE
Description: the standard 2VE technique for ventilation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2VE
Description: the standard 2VE technique for ventilation
Study: NCT04713488

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sputnik Light
Description: solution for intramuscular injection Composition for 1 dose (0.5 ml)
Study: NCT05753488

Intervention type: DIAGNOSTIC_TEST
Intervention: graft function
Description: renal transplantation

Intervention type: DIAGNOSTIC_TEST
Intervention: graft function
Description: renal transplantation
Study: NCT05059366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2VE
Description: the standard 2VE technique for ventilation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2VE
Description: the standard 2VE technique for ventilation
Study: NCT05404087

Intervention type: DEVICE
Intervention: Dedicated breast CT
Description: Administration of contrast agent and scanning of the breast in order to evaluate the enhancement of the tumor

Intervention type: DEVICE
Intervention: Dedicated breast CT
Description: Administration of contrast agent and scanning of the breast in order to evaluate the enhancement of the tumor
Study: NCT06433323

Intervention type: OTHER
Intervention: Anti-aging cosmetic care product
Description: This is an intra-individual comparison study.~* frequency of application: Once a day (in the evening)~* modalities of application: Apply the cream on the tested area determined by the randomization~* duration of investigational product application: 56 days (a window of + 72 hours is allowed)
Study: NCT06263894

Intervention type: OTHER
Group type: OTHER
Intervention: Experimental group
Description: Alexander technique will be applied to the experimental group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Alexander technique will be applied to the experimental group.
Study: NCT05817838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: For six months, families will receive weekly, $15 financial incentives to purchase healthy foods and beverages at a partnering Southeast Asian grocery store

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives and Multilevel Multicomponent
Description: For six months, families will receive weekly, $15 financial incentives to purchase healthy foods and beverages at a partnering Southeast Asian grocer store, in-person, group-based nutrition education with other Southeast Asian families, text messages and motivational interviewing

Intervention type: OTHER
Group type: OTHER
Intervention: School Engagement
Description: For six months, families will attend in-person, group-based school engagement education with other Southeast Asian families designed to improve youths' academic outcomes. Families will receive text messages and motivational interviews. At the end of the six months, families will receive the equivalent of the six months worth of weekly, $15 financial incentives.
Study: NCT05745311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The KPCXM18 injection
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The KPCXM18 injection
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The KPCXM18 injection
Description: Intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion
Study: NCT05340738

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LyssnCBT
Description: LyssnCBT is a technology that allows therapists and supervisors access to tools that assist with assessing CBT session fidelity, including speech-to-text transcription, annotation tools, and AI-generated metrics.
Study: NCT06437262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.20% CHX gel on saliva
Description: In vivo application of a gel on the vestibular and palatal/lingual gingival mucosa of both arches at minute 0 for posterior saliva collection at different time-points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.20% CHX and Cymenol gel on saliva
Description: In vivo application of a gel on the vestibular and palatal/lingual gingival mucosa of both arches at minute 0 for posterior saliva collection at different time-points.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.20% CHX gel on oral biofilm
Description: Ex vivo application of a gel on the glass disks of the removable intraoral appliance at minute 0 for subsequent one-by-one disk removal from the device at different time-points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.20% CHX and Cymenol gel on oral biofilm
Description: Ex vivo application of a gel on the glass disks of the removable intraoral appliance at minute 0 for subsequent one-by-one disk removal from the device at different time-points.
Study: NCT06000748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAP-Target Algorithm
Description: This is a clinical treatment algorithm that will determine the escalation and deescalation of vasoconstrictor utilization based on a target MAP, either high (≥80 mmHg) in the treatment group and low (\< 80 mmHg) in the comparator group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAP-Target Algorithm
Description: This is a clinical treatment algorithm that will determine the escalation and deescalation of vasoconstrictor utilization based on a target MAP, either high (≥80 mmHg) in the treatment group and low (\< 80 mmHg) in the comparator group.
Study: NCT05319509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gameChange
Description: Staff will explain the rationale behind gameChange, and briefly explain the different scenarios: a doctor's office, a waiting room, a pub, a café, a grocery store, a public street and a bus. Each scenario contains five levels, each increasing with anxiety stimuli and certain tasks the participant must complete. The participant will put on the Oculus headset, and go through a preliminary orientation game. The headset will be casted to an external monitor. Once they start gameChange, it will take the participants to the virtual therapist's room. They will be asked to choose which scenario they would like to participate in first and will complete all five levels for one scenario. Research staff will be taking event sampling-style observations of the participant. After completion of the levels, the participant will return to the virtual therapist's room for debriefing, and then will be asked to exit the game.
Study: NCT05666765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin ,silymarin
Description: 20mg/day isotretinoin for 3 months. 140 mg/day silymarin for 3 months. 20mg/day isotretinoin and 140mg/day silymarin for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin ,silymarin
Description: 20mg/day isotretinoin for 3 months. 140 mg/day silymarin for 3 months. 20mg/day isotretinoin and 140mg/day silymarin for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin ,silymarin
Description: 20mg/day isotretinoin for 3 months. 140 mg/day silymarin for 3 months. 20mg/day isotretinoin and 140mg/day silymarin for 3 months.
Study: NCT06333795

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Faecal Microbiota Transplantation (FMT)
Description: Treatment is given as capsules.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment is given as capsules.
Study: NCT05273320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabilone
Description: Nabilone capsules at a maximum dose of 1 mg twice a day
Study: NCT06457061

Intervention type: OTHER
Intervention: Survey Study
Description: Barthel Index for Activities of Daily Living Scale, Beck Depression Inventory and Star Cancellation Test questionnaires were applied to hemiplegia patients.~Beck Depression Inventory and Zarit Caregiver Burden Interview surveys were administered to caregivers.

Intervention type: OTHER
Intervention: Survey Study
Description: Barthel Index for Activities of Daily Living Scale, Beck Depression Inventory and Star Cancellation Test questionnaires were applied to hemiplegia patients.~Beck Depression Inventory and Zarit Caregiver Burden Interview surveys were administered to caregivers.
Study: NCT05201508

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polyglactin mesh
Description: Polyglactin mesh is used in keyhole manner to enforce hiatal closure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sutures only
Description: Traditional hiatal closure with non-absorbable sutures.
Study: NCT06409910

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Non-institutional-standard radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Non-institutional-standard radiotherapy
Study: NCT05597033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: walking and handgrip exercise
Study: NCT05204212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage closure
Description: Percutaneous closure of the LAA
Study: NCT04933383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQ001S 0.125 mg/ml
Description: administered by nebulization once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AQ001S 0.125 mg/ml
Description: administered by nebulization once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 0.125 mg/ml inhalation suspension
Description: administered by nebulization once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide 0.125 mg/ml inhalation suspension
Description: administered by nebulization once daily
Study: NCT05385653

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: experimentation of the virtual reality RevBED
Description: ReVBED is a VR-based exposure scenario for CBT for the induction of food craving in patients with bulimia nervosa and binge eating disorder.~The use of ReVBED requires no VR experience and only generic and commonly used virtual reality tools (a computer with VR software, a wireless virtual reality headset, two controllers and headphones), all with a CE mark, allowing its users to move in and interact with a specially designed virtual environment.~This exhibit scenario takes place in a VR environment built to represent a standard apartment consisting of four exhibit rooms (a bedroom, a teenager's bedroom, a living room and a kitchen) in which the ReVBED user moves sequentially through the scenario. In each room, specific cues of craving are displayed. These cues are not only visual, but also audio, emotional and socio-environmental. A central hall connects the other rooms and serves as a safe place for debriefing, where measures such as craving are assessed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experimentation of the virtual reality RevBED
Description: ReVBED is a VR-based exposure scenario for CBT for the induction of food craving in patients with bulimia nervosa and binge eating disorder.~The use of ReVBED requires no VR experience and only generic and commonly used virtual reality tools (a computer with VR software, a wireless virtual reality headset, two controllers and headphones), all with a CE mark, allowing its users to move in and interact with a specially designed virtual environment.~This exhibit scenario takes place in a VR environment built to represent a standard apartment consisting of four exhibit rooms (a bedroom, a teenager's bedroom, a living room and a kitchen) in which the ReVBED user moves sequentially through the scenario. In each room, specific cues of craving are displayed. These cues are not only visual, but also audio, emotional and socio-environmental. A central hall connects the other rooms and serves as a safe place for debriefing, where measures such as craving are assessed.
Study: NCT06582238

Intervention type: OTHER
Intervention: Dentists in Clinical Practice
Description: Experience in managing Dentine Hypersensitivity
Study: NCT05597033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: walking and handgrip exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: seated rest

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: seated rest
Study: NCT06108219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant (Cohort A)
Description: Miricorilant 100 mg for oral dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Cohort A)
Description: Matching placebo for oral dosing for 48 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant (Cohort B)
Description: Miricorilant 100 mg for oral dosing Miricorilant 200 mg for oral dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Cohort B)
Description: Matching placebo for oral dosing for 24 Weeks
Study: NCT04843436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symani Surgical System
Description: Robotically Assisted Microsurgery
Study: NCT05432284

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (ambient air)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Pure THC vapor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Pure THC vapor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Pure THC vapor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Pure THC vapor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Pure THC vapor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Pure THC vapor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-Myrcene
Description: Pure beta-myrcene vapor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-Myrcene
Description: Pure beta-myrcene vapor
Study: NCT05478356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-dose atropine eye drops
Description: low-dose atropine eye drops
Study: NCT05432284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-Myrcene
Description: Pure beta-myrcene vapor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-Myrcene
Description: Pure beta-myrcene vapor
Study: NCT05478356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthokeratology
Description: orthokeratology, ortho-K lenses
Study: NCT05922189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SBS Decompression Technique
Description: The investigator who applied the technique stood on the right side, laterally to the headboard of the table, with feet flat on the floor, at an appropriate level in relation to the volunteer's headboard, and with a glove on his right hand. Then, he contacted the volunteer's sphenoid wings with his left hand and asked the volunteer to open her mouth, contacting the upper dental arch with the second and third fingers of his right hand. Subsequently, the investigator brought both hands together, followed by an inspiration towards the floor and then a translation towards the ceiling until he felt the structures relax, with a maximum duration of 5 minutes. A second Investigator was sitting on a chair, placed on the opposite side of the head of the table with a stopwatch in his dominant hand, in order to time the application time of each technique.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Technique
Description: The investigator was standing, on the right side, laterally to the headboard of the table with feet flat on the floor, at an appropriate level in relation to the headboard of the volunteer's and with a glove on his right hand. Then, he contacted the participant's sphenoid wings with his left hand and asked her to open her mouth. With the second and third fingers of the right hand, he made contact with the upper dental arch. These contacts were maintained for 2 minutes, without moving. A second investigator sat on a chair, placed on the opposite side of the table with the stopwatch in his dominant hand, in order to time the application time of each technique.
Study: NCT06219096

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIF image-guided laparoscopic anatomical liver resection with the novel ICG@HSA administration
Description: After ligation of the target hepatic segmental portal vein, the novel ICG regimen (0.5 mg ICG powder and 500 mg human serum albumin added to 20 ml saline, shaken and allowed to stand for more than 5 minutes, ICG: 0.025 mg/ml, human serum albumin: 25 mg/ml) was intravenously infused continuously at a rate of 1 ml/min until significant fluorescence imaging appeared in the demarcated area, upon which the infusion was terminated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NIF image-guided laparoscopic anatomical liver resection with the guideline-recommended ICG administration
Description: After ligation of the target hepatic segmental portal vein, 2.5 mg of ICG (2.5 mg/ml) was intravenously injected.
Study: NCT06461832

Intervention type: PROCEDURE
Intervention: Group 1
Description: In patients undergoing a hysterectomy, an epidural catheter is placed via the L3-4 or L4-5 spinal space, followed by the application of a standardized general anesthesia protocol.

Intervention type: PROCEDURE
Intervention: Group 2
Description: In patients undergoing hysterectomy, 15-20 mg of heavy bupivacaine is injected into the intrathecal area via the L3-4 or L4-5 spinal space, using a spinal needle. Following the removal of the spinal needle, an epidural catheter is then placed through the same opening.
Study: NCT04818970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow Band ultraviolet B-Band Light
Description: Daily doses of NB-UVB for 8 consecutive days.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: non Narrow Band ultraviolet B-Band Light
Description: Daily doses of non-NB-UVB for 8 consecutive days.
Study: NCT05083533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tele-rehabilitation exercise
Description: Telerehabilitation allows patients to interact with providers remotely and can be used both to assess patients and to deliver therapy. Treatment program planned to stretch the muscles of individuals with short hamstring muscle group.~Stretching exercises for hamstring muscle group shortening were applied 4 days a week, which lasted for 8 weeks in total. For the first four weeks, 3 different stretching exercises per day were planned and performed as 10 seconds of stretching and 5 repetitions. For the last four weeks, 4 different stretching exercises were planned per day and performed with 20 seconds of stretching and 10 repetitions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: All participants received home exercise for 8 weeks. The exercise program includes stretching exercises Stretching exercises for hamstring muscle group shortening were applied 4 days a week, which lasted for 8 weeks in total. For the first four weeks, 3 different stretching exercises per day were planned and performed as 10 seconds of stretching and 5 repetitions. For the last four weeks, 4 different stretching exercises were planned per day and performed with 20 seconds of stretching and 10 repetitions.
Study: NCT04869540

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Evidence based care for transition-aged youth (TAY) with ASD.